Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARAV NASDAQ:MNPR NASDAQ:NATR NASDAQ:OVID On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAVAravive$0.04$0.04$0.04▼$2.46N/AN/AN/AN/AMNPRMonopar Therapeutics$63.86+12.3%$55.94$28.40▼$105.00$381.03M1.49161,800 shs288,487 shsNATRNature's Sunshine Products$26.24+1.2%$25.70$12.90▼$28.14$453.71M0.9572,648 shs55,488 shsOVIDOvid Therapeutics$2.78-1.8%$2.34$0.27▼$3.11$373.20M0.182.69 million shs2.57 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAVAravive0.00%0.00%0.00%0.00%0.00%MNPRMonopar Therapeutics+12.27%+27.41%+18.96%+12.27%+63.13%NATRNature's Sunshine Products+1.23%-2.92%+6.67%0.00%+111.44%OVIDOvid Therapeutics-1.77%+3.35%+20.87%+91.72%+869.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAVAravive$0.04$0.04$0.04▼$2.46N/AN/AN/AN/AMNPRMonopar Therapeutics$63.86+12.3%$55.94$28.40▼$105.00$381.03M1.49161,800 shs288,487 shsNATRNature's Sunshine Products$26.24+1.2%$25.70$12.90▼$28.14$453.71M0.9572,648 shs55,488 shsOVIDOvid Therapeutics$2.78-1.8%$2.34$0.27▼$3.11$373.20M0.182.69 million shs2.57 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAVAravive0.00%0.00%0.00%0.00%0.00%MNPRMonopar Therapeutics+12.27%+27.41%+18.96%+12.27%+63.13%NATRNature's Sunshine Products+1.23%-2.92%+6.67%0.00%+111.44%OVIDOvid Therapeutics-1.77%+3.35%+20.87%+91.72%+869.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARAVAravive 0.00N/AN/AN/AMNPRMonopar Therapeutics 3.00Buy$107.0067.55% UpsideNATRNature's Sunshine Products 3.00Buy$31.0018.14% UpsideOVIDOvid Therapeutics 2.89Moderate Buy$4.6366.37% UpsideCurrent Analyst Ratings BreakdownLatest ARAV, MNPR, NATR, and OVID Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026MNPRMonopar Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026OVIDOvid Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026OVIDOvid Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$7.004/9/2026OVIDOvid Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.00 ➝ $4.003/30/2026MNPRMonopar Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.003/26/2026OVIDOvid Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.003/20/2026NATRNature's Sunshine Products Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)3/20/2026OVIDOvid Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$5.00 ➝ $7.003/12/2026NATRNature's Sunshine Products DA DavidsonSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$23.00 ➝ $33.003/10/2026NATRNature's Sunshine Products Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$22.00 ➝ $29.002/23/2026MNPRMonopar Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$104.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARAVAraviveN/AN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/A$20.62 per shareN/ANATRNature's Sunshine Products$480.14M0.96$2.20 per share11.92$9.23 per share2.84OVIDOvid Therapeutics$7.25M50.57N/AN/A$1.00 per share2.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARAVAraviveN/A-$0.90N/AN/AN/AN/AN/AN/AN/AMNPRMonopar Therapeutics-$13.72M-$1.82N/AN/AN/AN/A-14.24%-13.93%5/12/2026 (Estimated)NATRNature's Sunshine Products$19.52M$1.0624.75N/AN/A4.07%14.36%9.16%5/7/2026 (Estimated)OVIDOvid Therapeutics-$17.41M-$0.31N/AN/AN/A-240.11%-23.98%-18.63%5/12/2026 (Estimated)Latest ARAV, MNPR, NATR, and OVID EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026MNPRMonopar Therapeutics-$0.8975N/AN/AN/AN/AN/A5/12/2026Q1 2026OVIDOvid Therapeutics-$0.12N/AN/AN/A$0.06 millionN/A5/7/2026Q1 2026NATRNature's Sunshine Products$0.2250N/AN/AN/A$122.75 millionN/A3/27/2026Q4 2025MNPRMonopar Therapeutics-$0.5123-$0.61-$0.0977-$0.61N/AN/A3/18/2026Q4 2025OVIDOvid Therapeutics-$0.10$0.06+$0.16$0.06$0.06 million$0.72 million3/10/2026Q4 2025NATRNature's Sunshine Products$0.19$0.30+$0.11$0.23$121.62 million$123.81 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARAVAraviveN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ANATRNature's Sunshine ProductsN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARAVAraviveN/AN/AN/AMNPRMonopar TherapeuticsN/A51.3651.36NATRNature's Sunshine ProductsN/A2.281.41OVIDOvid Therapeutics0.098.978.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARAVAravive35.80%MNPRMonopar Therapeutics1.83%NATRNature's Sunshine Products79.40%OVIDOvid Therapeutics72.24%Insider OwnershipCompanyInsider OwnershipARAVAravive60.40%MNPRMonopar Therapeutics20.50%NATRNature's Sunshine Products3.10%OVIDOvid Therapeutics13.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARAVAravive20N/AN/ANo DataMNPRMonopar Therapeutics106.70 million5.33 millionNot OptionableNATRNature's Sunshine Products85017.51 million16.97 millionOptionableOVIDOvid Therapeutics60131.88 million114.60 millionOptionableARAV, MNPR, NATR, and OVID HeadlinesRecent News About These CompaniesOvid Therapeutics (OVID) to Release Earnings on TuesdayMay 5 at 1:06 PM | marketbeat.comOvid Therapeutics (NASDAQ:OVID) Sees Large Decline in Short InterestApril 29, 2026 | marketbeat.comOvid Therapeutics Inc.April 20, 2026 | edition.cnn.comOvid Therapeutics (NASDAQ:OVID) Given Average Recommendation of "Buy" by AnalystsApril 20, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Ovid Therapeutics (OVID) and Legend Biotech (LEGN)April 17, 2026 | theglobeandmail.comOvid Therapeutics' (OVID) "Outperform" Rating Reiterated at WedbushApril 15, 2026 | marketbeat.comOvid Therapeutics: Differentiated KCC2 ‘Master Switch’ Platform and Strong Cash Runway Underpin Buy RatingApril 15, 2026 | tipranks.comOvid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders TranscriptApril 14, 2026 | seekingalpha.comShort Interest in Ovid Therapeutics (NASDAQ:OVID) Increases By 71.2%April 13, 2026 | marketbeat.comHC Wainwright Issues Positive Forecast for OVID EarningsApril 13, 2026 | marketbeat.comOvid Therapeutics (NASDAQ:OVID) Price Target Raised to $4.00April 9, 2026 | marketbeat.comOvid Therapeutics: Undervalued KCC2 Platform and Upcoming OV4071 Catalyst Support Buy RatingApril 9, 2026 | tipranks.comOvid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14April 8, 2026 | globenewswire.comOvid Therapeutics (OVID) price target increased by 14.29% to 4.87March 27, 2026 | msn.comAnalysts Are Bullish on Top Healthcare Stocks: Sera Prognostics (SERA), Ovid Therapeutics (OVID)March 20, 2026 | theglobeandmail.comOvid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE FundingMarch 20, 2026 | seekingalpha.comOvid Therapeutics Raises Capital to Expand Epilepsy PipelineMarch 20, 2026 | theglobeandmail.comRegulatory Timing Risks Mount for Ovid Therapeutics as FDA Funding and Staffing Volatility Threaten Drug Approval TimelinesMarch 20, 2026 | tipranks.comWhy Ovid Therapeutics Inc.’s (OVID) Stock Is Up 19.31%March 19, 2026 | aaii.comAOvid Therapeutics advances OV329 epilepsy drug, secures $60M financingMarch 19, 2026 | msn.comOvid Therapeutics Shares Rise After Swinging to 4Q Profit, Expanding TreatmentMarch 19, 2026 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARAV, MNPR, NATR, and OVID Company DescriptionsAravive NASDAQ:ARAV$0.04 0.00 (0.00%) As of 05/5/2026Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.Monopar Therapeutics NASDAQ:MNPR$63.86 +6.98 (+12.27%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$63.78 -0.08 (-0.13%) As of 05/6/2026 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Nature's Sunshine Products NASDAQ:NATR$26.24 +0.32 (+1.23%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$26.24 0.00 (0.00%) As of 05/6/2026 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.Ovid Therapeutics NASDAQ:OVID$2.78 -0.05 (-1.77%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$2.80 +0.02 (+0.72%) As of 05/6/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Apple Talks Just Changed Everything for Intel Consolidate or Die: Is Rivian The Ultimate Takeover Target? Years in the Making, AMD’s Upside Movement Has Just Begun Capital One’s Big Bet Faces Rising Credit Risk Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
